<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602068</url>
  </required_header>
  <id_info>
    <org_study_id>EGP-437-005</org_study_id>
    <nct_id>NCT01602068</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyegate Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyegate Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with
      dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery
      System (EGDS) compared to placebo in patients undergoing cataract surgery with implantation
      of a posterior chamber intraocular lens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2, proof-of-concept (POC) clinical trial designed to evaluate the safety and efficacy
      of ocular iontophoretic delivery of dexamethasone phosphate ophthalmic solution compared to
      ocular iontophoresis with a placebo (100 mM citrate buffer of pH 5.7) in patients planning to
      have cataract surgery with implantation of a posterior chamber intraocular lens (IOL). The
      population studied was comprised of males and females scheduled for unilateral cataract
      surgery with implantation of a posterior chamber IOL. Eligible patients were enrolled into
      the study and were randomized on Day 1 in a 1:1 ratio into one of the following two treatment
      arms. Treatments were administered on the day prior (Day -1) to cataract surgery (Day 0).
      Subjects were scheduled to return to the clinic on Days 1, 7, 14, and 28. All subjects were
      scheduled to exit the study on Day 28. Subjects were asked to complete a daily pain score
      assessment questionnaire for the first 14 days post-surgery (Days 0 - 14).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With AC Cell Count of Zero on Day 7</measure>
    <time_frame>At Day 7 (plus or minus two days) following the study treatment</time_frame>
    <description>Proportion of patients with anterior chamber (AC) cell count of zero on Day 7 as compared between the active and placebo groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Phosphate Ophthalmic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mM Sodium Citrate Buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Phosphate Ophthalmic</intervention_name>
    <description>Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)</description>
    <arm_group_label>Dexamethasone Phosphate Ophthalmic</arm_group_label>
    <other_name>Active arm, Arm 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mM Sodium Citrate Buffer</intervention_name>
    <description>Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution</description>
    <arm_group_label>100 mM Sodium Citrate Buffer</arm_group_label>
    <other_name>In-active control arm, Arm 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing unilateral cataract extraction and implantation of a monofocal IOL (at the
             time of enrollment)

          -  Male or female 18 years or older

          -  Receive, understand, and sign a copy of the written informed consent form

          -  Be able to return for all study visits and willing to comply with all study-related
             instructions

        Exclusion Criteria:

          -  Subjects not meeting the inclusion criteria

          -  Subjects being implanted with a multifocal IOL

          -  Ocular surgery of any kind in the study eye within 6 months prior to baseline visit

          -  Cataract surgery on the fellow eye within 6 weeks, including 2 weeks without topical
             ocular medication, prior to baseline visit

          -  Scheduled for surgery in the fellow eye within the study period

          -  Have anterior chamber inflammation as measured by slit lamp examination at baseline.
             Anterior chamber cell and/or flare grade &gt; 0

          -  Have used any topical ocular medication in either eye, other than tear substitute for
             dry eye, at least 2 weeks prior to baseline visit

          -  Have IOP ≥ 25 mmHg at baseline, a history of glaucoma, or require ocular
             anti-hypertensive medications

          -  Be known corticosteroid intraocular pressure responder in either eye

          -  Have used topical corticosteroid or NSAID treatment in either eye ≤ 48 hours prior to
             baseline visit

          -  Systemic administration of corticosteroid within the past 14 days prior to baseline
             visit

          -  Have received intravitreal, sub-Tenon's, or any periocular corticosteroid treatment in
             either eye within the past 6 months prior to baseline visit

          -  Have open wounds/ skin disease on the forehead area where the iontophoresis return
             electrode will be applied

          -  Have severe lesions of the eyelids or the ocular surface impeding the application of
             the iontophoresis applicator

          -  Have blepharospasm, blepharophimosis, or other eyelid anatomic variations precluding
             the placement of the iontophoresis applicator

          -  Have significant Fuch's Corneal Dystrophy

          -  Have known allergy to dexamethasone or dexamethasone phosphate or any medication to be
             used in this study

          -  Have history or diagnosis of ocular herpes, corneal lesion of suspected herpetic
             origin

          -  Have optic neuritis of any origin

          -  Have clinically suspected or confirmed central nervous system or ocular lymphoma

          -  Have active hyphema, pars planitis, choroiditis, Behçet's disease, clinically
             significant macular edema, toxoplasmosis scar, or vitreous hemorrhage

          -  Have severe/serious ocular pathology or medical condition which may preclude study
             completion

          -  History of HIV/AIDS

          -  Have pacemaker and/or any other electrical sensitive support system

          -  Be pregnant or lactating female, or female of childbearing age and using inadequate
             birth control method

          -  Have participated in another investigational device or drug study within 30 days of
             baseline visit

          -  Have already participated in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Trattler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center For Excellence In Eye Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 501</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 503</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 502</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <results_first_submitted>November 18, 2014</results_first_submitted>
  <results_first_submitted_qc>May 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2018</results_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iontophoresis</keyword>
  <keyword>Cataract Surgery</keyword>
  <keyword>Ophthalmology</keyword>
  <keyword>Posterior Chamber Intraocular Lens Implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male or female patients at least 12 years of age and undergoing unilateral cataract surgery with implantation of a posterior chamber IOL could be screened</recruitment_details>
      <pre_assignment_details>1:1 randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone Phosphate Ophthalmic</title>
          <description>Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
        </group>
        <group group_id="P2">
          <title>100 mM Sodium Citrate Buffer</title>
          <description>Placebo (100 mM sodium citrate buffer solution) delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23">Day before surgery</participants>
                <participants group_id="P2" count="22">Day before surgery</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients planning to undergo a unilateral, posterior IOL.</population>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone Phosphate Ophthalmic</title>
          <description>Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
        </group>
        <group group_id="B2">
          <title>100 mM Sodium Citrate Buffer</title>
          <description>Placebo (100 mM sodium citrate buffer solution) delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="12" upper_limit="81"/>
                    <measurement group_id="B2" value="65" lower_limit="50" upper_limit="80"/>
                    <measurement group_id="B3" value="62" lower_limit="12" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With AC Cell Count of Zero on Day 7</title>
        <description>Proportion of patients with anterior chamber (AC) cell count of zero on Day 7 as compared between the active and placebo groups</description>
        <time_frame>At Day 7 (plus or minus two days) following the study treatment</time_frame>
        <population>This was an exploratory study and therefore a number of efficacy and safety parameters were evaluated. In all measures there was no significant difference between the active and non-active arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Phosphate Ophthalmic</title>
            <description>Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
          </group>
          <group group_id="O2">
            <title>100 mM Sodium Citrate Buffer</title>
            <description>Placebo (100 mM sodium citrate buffer solution) delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With AC Cell Count of Zero on Day 7</title>
          <description>Proportion of patients with anterior chamber (AC) cell count of zero on Day 7 as compared between the active and placebo groups</description>
          <population>This was an exploratory study and therefore a number of efficacy and safety parameters were evaluated. In all measures there was no significant difference between the active and non-active arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the point that the ICF was signed. All AEs until the last day of the study, through resolution, stabilization, or at least 30 days after treatment, whichever occurs first.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone Phosphate Ophthalmic</title>
          <description>Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
        </group>
        <group group_id="E2">
          <title>100 mM Sodium Citrate Buffer</title>
          <description>Placebo (100 mM sodium citrate buffer solution) delivered by transcleral iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Not related. Between Visits 5 &amp; 6.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Not related. Between Visits 5 &amp; 6.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <description>Not related. Between Visits 5 &amp; 6.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular AE</sub_title>
                <description>In Study eye</description>
                <counts group_id="E1" events="84" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E2" events="70" subjects_affected="20" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>The surgical procedure eliminates or washes out any remaining study drug product from the ocular tissue which becomes inflamed post-surgery. Exploratory study with multiple efficacy &amp; safety parameters were evaluated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa Brandano</name_or_title>
      <organization>Eyegate Pharmaceuticals, Inc.</organization>
      <phone>781-398-3806</phone>
      <email>lbrandano@eyegatepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

